Detalhe da pesquisa
1.
Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non-Small Cell Lung Cancer from the PACIFIC Study.
Curr Ther Res Clin Exp
; 95: 100640, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34484473
2.
Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108.
Cancer
; 126(2): 432-443, 2020 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31581306
3.
Statistical and practical considerations in designing of immuno-oncology trials.
J Biopharm Stat
; 30(6): 1130-1146, 2020 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33706684
4.
Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer.
Gynecol Oncol
; 138(1): 18-23, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25925990
5.
Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of ßIII-tubulin expression as a predictive marker.
Oncologist
; 18(7): 787-94, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23853246
6.
Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients.
Breast Cancer Res Treat
; 142(2): 381-8, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24166282
7.
Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer.
Cancer
; 118(2): 461-8, 2012 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21598243
8.
Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials.
Support Care Cancer
; 20(11): 2661-8, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22382588
9.
Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis.
JAMA Oncol
; 8(9): 1294-1300, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35862037
10.
SAEgnal: A Predictive Assessment Framework for Optimizing Safety Profiles in Immuno-Oncology Combination Trials.
AMIA Jt Summits Transl Sci Proc
; 2021: 535-544, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34457169
11.
Correlation Between Early Endpoints and Overall Survival in Non-Small-Cell Lung Cancer: A Trial-Level Meta-Analysis.
Front Oncol
; 11: 672916, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34381708
12.
Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
Breast Cancer Res Treat
; 122(2): 409-18, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20454927
13.
Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-Analysis.
Clin Pharmacol Ther
; 108(6): 1274-1288, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32564368
14.
Optimal PD-L1-high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy.
PLoS One
; 15(4): e0231936, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32339189
15.
Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations.
Pharmacoeconomics
; 37(9): 1129-1138, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31102143
16.
Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients.
Clin Lung Cancer
; 20(6): e601-e608, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31327642
17.
The MaxCombo Test Severely Violates the Type I Error Rate-Reply.
JAMA Oncol
; 9(4): 572, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36757709
18.
Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients With Urothelial Carcinoma.
Clin Pharmacol Ther
; 103(4): 643-652, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29243222
19.
Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status.
Clin Pharmacol Ther
; 103(4): 631-642, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29243223
20.
Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer.
JAMA Oncol
; 6(7): 1115-1116, 2020 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32352489